Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Pituitary Gland01:17

The Pituitary Gland

The pituitary is a small endocrine organ in the sphenoid bone under the hypothalamus. Primarily, the pituitary in adults has two distinct anatomical and functional regions— the anterior and posterior lobes. During human fetal development, a third pituitary gland region called the pars intermedia atrophies and disappears. However, some of its cells migrate and exist adjacent to the anterior pituitary in adults.
Hormones of the Pituitary Gland01:27

Hormones of the Pituitary Gland

The small, pea-sized pituitary gland is located at the base of the brain. It is crucial in regulating various bodily functions, from growth to reproduction. The gland is divided into the anterior lobe and the posterior lobe. The secretory cell clusters in the pars distalis of the anterior pituitary lobe are controlled by hypothalamic regulators and synthesize six primary hormones.
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
Hypothalamic-Pituitary Axis01:37

Hypothalamic-Pituitary Axis

The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor.
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Regulation of Hormone Secretion01:19

Regulation of Hormone Secretion

Regulation of hormone secretion is a finely tuned orchestration driven by various types of stimuli, encompassing neural, humoral, and hormonal signals. Environmental cues instigate neural stimuli, where action potentials traverse nerve fibers to reach their designated targets. An illustrative scenario is the body's response to stress, wherein the sympathetic nervous system releases epinephrine from the adrenal glands, inducing the well-known 'fight or flight' reaction.
Humoral stimuli,...
Major Hormones and Their Functions01:27

Major Hormones and Their Functions

Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study.

Journal of child and adolescent psychopharmacology·2017
Same author

Does Visceral or Subcutaneous Fat Influence Peripheral Cortical Bone Strength During Adolescence? A Longitudinal Study.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2017
Same author

The Effect of Depression, Generalized Anxiety, and Selective Serotonin Reuptake Inhibitors on Change in Bone Metabolism in Adolescents and Emerging Adults.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2017
Same author

Bone Mass in Boys with Autism Spectrum Disorder.

Journal of autism and developmental disorders·2017
Same author

The Relationship Between Greater Prepubertal Adiposity, Subsequent Age of Maturation, and Bone Strength During Adolescence.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2016
Same author

Fat distribution and major depressive disorder in late adolescence.

The Journal of clinical psychiatry·2015

Related Experiment Video

Updated: Jun 5, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Update in pituitary 2010.

Janet A Schlechte1

  • 1Department of Internal Medicine, University of Iowa, Iowa City, Iowa 52242, USA. janet-schlechte@uiowa.edu

The Journal of Clinical Endocrinology and Metabolism
|January 7, 2011
PubMed
Summary

This review covers recent advances in pituitary disease management, focusing on dopamine agonist safety in pregnancy and treatment outcomes for hyperprolactinemia and acromegaly.

Area of Science:

  • Endocrinology
  • Pituitary Disorders
  • Pharmacology

Background:

  • The management of pituitary diseases requires continuous updates on evolving therapeutic strategies and safety profiles.
  • Recent literature highlights key areas of concern and progress in treating conditions like hyperprolactinemia and acromegaly.

Purpose of the Study:

  • To review significant advancements and emerging issues in pituitary disease management published between January 2009 and June 2010.
  • To provide an overview of critical updates for clinicians managing pituitary disorders.

Main Methods:

  • Literature review of papers published in major journals from January 2009 to June 2010.
  • Focus on specific topics including dopamine agonist use in pregnancy, treatment withdrawal, and mortality predictors.

More Related Videos

Dissection and Coronal Slice Preparation of Developing Mouse Pituitary Gland
06:53

Dissection and Coronal Slice Preparation of Developing Mouse Pituitary Gland

Published on: November 16, 2017

Development of Organoids from Mouse Pituitary as In Vitro Model to Explore Pituitary Stem Cell Biology
09:48

Development of Organoids from Mouse Pituitary as In Vitro Model to Explore Pituitary Stem Cell Biology

Published on: February 25, 2022

Related Experiment Videos

Last Updated: Jun 5, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Dissection and Coronal Slice Preparation of Developing Mouse Pituitary Gland
06:53

Dissection and Coronal Slice Preparation of Developing Mouse Pituitary Gland

Published on: November 16, 2017

Development of Organoids from Mouse Pituitary as In Vitro Model to Explore Pituitary Stem Cell Biology
09:48

Development of Organoids from Mouse Pituitary as In Vitro Model to Explore Pituitary Stem Cell Biology

Published on: February 25, 2022

Main Results:

  • Cabergoline demonstrates safety during pregnancy for managing hyperprolactinemia.
  • Recurrence of hyperprolactinemia after dopamine agonist withdrawal is a notable concern.
  • Pegvisomant use is associated with potential hepatic dysfunction.
  • High-dose hydrocortisone predicts mortality in acromegaly patients.

Conclusions:

  • Ongoing research refines the understanding of safety and efficacy for pituitary disease treatments.
  • Clinicians must consider specific patient factors and emerging data for optimal management.
  • Further investigation is warranted for long-term outcomes and safety of various therapeutic agents.